About: Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS‐CoV‐2 infection: a retrospective cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS‐CoV‐2 infection: a retrospective cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS‐CoV‐2 infection: a retrospective cohort study
Creator	Antinori, Spinello Galli, Massimo Rusconi, Stefano Casalini, Giacomo Cattaneo, Dario Colombo, Riccardo Gervasoni, Cristina Giacomelli, Andrea Oreni, Letizia Pagani, Gabriele Pezzati, Laura Ridolfo, Anna Rizzardini, Giuliano Morena, Valentina Ceriani, Elisa Passerini, Simone Bassoli, Cinzia Bradanini, Lucia Bit, Federico Conti,
Source	Medline; PMC
abstract	BACKGROUND: As it has been shown that lopinavir (LPV) and hydroxychloroquine (HCQ) have in vitro activity against coronaviruses, they were used to treat COVID‐19 during the first wave of the epidemic in Lombardy, Italy. METHODS: To compare the rate of clinical improvement between those who started LPV/ritonavir (LPV/r)+HCQ within five days of symptom onset (early treatment, ET) and those who started later (delayed treatment, DT). This was a retrospective intent‐to‐treat analysis of the hospitalized patients who started LPV/r+HCQ between 21 February and 20 March 2020. The association between the timing of treatment and the probability of 30‐day mortality was assessed using uni‐ and multivariable logistic models. RESULTS: The study involved 172 patients: 43 (25%) in the ET and 129 (75%) in the DT group. The rate of clinical improvement increased over time to 73.3% on day 30, without any significant difference between the two groups (Gray's test P=0.213). After adjusting for potentially relevant clinical variables, there was no significant association between the timing of the start of treatment and the probability of 30‐day mortality (adjusted odds ratio [aOR] ET vs DT=1.45, 95% confidence interval 0.50‐4.19). Eight percent of the patients discontinued the treatment because of severe gastrointestinal disorders attributable to LPV/r. CONCLUSION: The timing of the start of LPV/r+HCQ treatment does not seem to affect the clinical course of hospitalised patients with COVID‐19. Together with the severe adverse events attributable to LPV/r, this raises concerns about the benefit of using this combination to treat COVID‐19. This article is protected by copyright. All rights reserved.
has issue date	2020-08-10(xsd:dateTime)
bibo:doi	10.1002/jmv.26407
bibo:pmid	32776534
has license	no-cc
sha1sum (hex)	22ee9b617f0f09cc1ed1586be2cf8051257f5fa3
schema:url	https://doi.org/10.1002/jmv.26407
resource representing a document's title	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS‐CoV‐2 infection: a retrospective cohort study
has PubMed Central identifier	PMC7436522
has PubMed identifier	32776534
schema:publication	J Med Virol
resource representing a document's body	covid:22ee9b617f0f09cc1ed1586be2cf8051257f5fa3#body_text
is schema:about of	named entity 'infection' named entity 'lopinavir/ritonavir' named entity 'plasma' named entity 'LPV' named entity 'adverse events' named entity 'LPV' named entity 'RNA' named entity 'nausea' named entity 'polymerase chain reaction' named entity 'HCQ' named entity 'COVID' named entity 'severe acute respiratory syndrome' named entity 'SARS' named entity 'Tropical Diseases' named entity 'supplementary oxygen' named entity 'COVID-19' named entity 'HCQ' named entity 'pharmacological' named entity 'COVID' named entity 'probability' named entity 'exponential increase' named entity 'randomised controlled trial' named entity 'hydroxychloroquine' named entity 'nasopharyngeal swab' named entity 'SARS-CoV-2' named entity 'diarrhoea' named entity 'Common Terminology Criteria for Adverse Events' named entity 'oxygen saturation' named entity 'statistically significant' named entity 'cumulative incidence' named entity 'clinical outcomes' named entity 'respiratory symptoms' named entity 'HCoV-229E' named entity 'gastro-intestinal disorders' named entity '23.5%' named entity 'demographic' named entity 'remdesivir' named entity 'Lombardy' named entity 'informed consent' named entity 'protein' named entity 'steroid' named entity 'coronavirus' named entity 'Fisher's exact test' named entity 'National Cancer Institute' named entity '2, 3' named entity 'allergy' named entity 'increased probability' named entity 'COVID-19' named entity 'COVID' named entity 'COVID' named entity 'Middle Eastern respiratory syndrome' named entity 'CSF' named entity 'liver' named entity 'HIV' named entity 'COVID' named entity 'Sacco Hospital' named entity 'antiviral activity' named entity 'treatment protocol' named entity 'SARS-CoV-2' named entity 'coronavirus disease 2019' named entity 'Western country' named entity 'severe pneumonia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software